AU5445699A - Remedies for spinal canal stenosis - Google Patents

Remedies for spinal canal stenosis

Info

Publication number
AU5445699A
AU5445699A AU54456/99A AU5445699A AU5445699A AU 5445699 A AU5445699 A AU 5445699A AU 54456/99 A AU54456/99 A AU 54456/99A AU 5445699 A AU5445699 A AU 5445699A AU 5445699 A AU5445699 A AU 5445699A
Authority
AU
Australia
Prior art keywords
spinal canal
canal stenosis
remedies
hydrogen atom
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54456/99A
Inventor
Toshiaki Akira
Tooru Kawamura
Hideaki Kido
Tomoyuki Maruyama
Norifumi Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Welfide Corp
Original Assignee
Nissan Chemical Corp
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp, Welfide Corp filed Critical Nissan Chemical Corp
Publication of AU5445699A publication Critical patent/AU5445699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

A therapeutic agent for spinal canal stenosis is provided, which contains a pyridazinone compound of the formula (I) <CHEM> wherein R<1>, R<2> and R<3> are each independently a hydrogen atom or a lower alkyl, X is a halogen atom, a cyano or a hydrogen atom, Y is a halogen atom, a trifluoromethyl or a hydrogen atom, and A is a C1 - C8 alkylene optionally substituted with a hydroxyl, or its pharmacologically acceptable salt. <IMAGE>
AU54456/99A 1998-09-01 1999-08-30 Remedies for spinal canal stenosis Abandoned AU5445699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24688698 1998-09-01
JP10/246886 1998-09-01
PCT/JP1999/004690 WO2000012091A1 (en) 1998-09-01 1999-08-30 Remedies for spinal canal stenosis

Publications (1)

Publication Number Publication Date
AU5445699A true AU5445699A (en) 2000-03-21

Family

ID=17155219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54456/99A Abandoned AU5445699A (en) 1998-09-01 1999-08-30 Remedies for spinal canal stenosis

Country Status (15)

Country Link
US (1) US6369061B1 (en)
EP (1) EP1123704B1 (en)
JP (1) JP4366865B2 (en)
KR (1) KR100573376B1 (en)
CN (1) CN1137686C (en)
AT (1) ATE272401T1 (en)
AU (1) AU5445699A (en)
CA (1) CA2342198C (en)
DE (1) DE69919191T2 (en)
DK (1) DK1123704T3 (en)
ES (1) ES2221421T3 (en)
PT (1) PT1123704E (en)
RU (1) RU2229297C2 (en)
TW (1) TW544312B (en)
WO (1) WO2000012091A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089411A1 (en) * 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. Remedy for spinal canal stenosis
CN1897952B (en) * 2003-12-26 2010-12-08 日产化学工业株式会社 Neutrophilia inhibitor
RU2339381C2 (en) * 2004-02-09 2008-11-27 Ниссан Кемикал Индастриз, Лтд. Preventer of blood vessels intima hyperplasia
KR20110098965A (en) 2008-12-23 2011-09-02 화이자 인코포레이티드 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA27031A1 (en) 1990-04-25 2000-02-28 Ніссан Кемікал Індастріз Лтд 3(2h) pyridazinone derivatives or pharmaceutically acceptable salts thereof, having antithrombotic, positive inotropic, vasodilating effect and antiallergic activity, and the pharmaceutical composition on the basis thereof
JP3806945B2 (en) 1994-01-21 2006-08-09 三菱ウェルファーマ株式会社 New use of human antithrombin-III
WO1995019969A1 (en) 1994-01-25 1995-07-27 Nissan Chemical Industries, Ltd. Pyridazinone derivative
IL112695A (en) 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
JPH09227411A (en) 1996-02-26 1997-09-02 Sumitomo Pharmaceut Co Ltd Therapeutic agent for neuropathy due to spinal cord injury

Also Published As

Publication number Publication date
CA2342198A1 (en) 2000-03-09
CN1325307A (en) 2001-12-05
ES2221421T3 (en) 2004-12-16
CN1137686C (en) 2004-02-11
ATE272401T1 (en) 2004-08-15
PT1123704E (en) 2004-10-29
EP1123704B1 (en) 2004-08-04
KR20010086361A (en) 2001-09-10
RU2229297C2 (en) 2004-05-27
DK1123704T3 (en) 2004-11-01
CA2342198C (en) 2007-08-28
DE69919191D1 (en) 2004-09-09
JP4366865B2 (en) 2009-11-18
TW544312B (en) 2003-08-01
EP1123704A1 (en) 2001-08-16
DE69919191T2 (en) 2005-07-28
US6369061B1 (en) 2002-04-09
KR100573376B1 (en) 2006-04-25
WO2000012091A1 (en) 2000-03-09
EP1123704A4 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
ATE239477T1 (en) QUINOLONES AND THEIR THERAPEUTIC USE
YU19002A (en) Quinolyl propyl piperidine derivatives, their preparation and compositions which contain them
CA2234567A1 (en) Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
MX9800718A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives.
DK0862562T3 (en) Benzoxazepine compounds, their preparation and their use as lipid level reducing agents
TR200001950T2 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds.
GB9801851D0 (en) Parasiticidal agents
HK1031867A1 (en) 2-phenoxyaniline derivatives
AU7810787A (en) 6-{2-(3-phenoxy-2-hydroxy-propylamino)-propyl-amino}-5- methyl-pyrizine-3-one derivatives useful as antihyper- tensive agents
AU5445699A (en) Remedies for spinal canal stenosis
AU3809095A (en) 6-polyfluoroalkoxy and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives
EP1121932A4 (en) Remedies for ocular diseases
EP0900785A3 (en) Vitamin A related compounds and process for producing the same
GR3031282T3 (en) New n-benzoylmethyl substituted paroxetine derivatives
CA2228078A1 (en) Composition for oral administration containing pyridazinone compounds
ATE238300T1 (en) (3,4-DIHYDRO-2H-BENZO(1,4)OXAZINYL-METHYL)-3-(1 - INDOL-3-YL)-ALKYLAMINES
HK1047431A1 (en) Benzamidine derivatives
RU2001108574A (en) THERAPEUTIC AGENT FOR TREATMENT OF SPENAL STENOSIS
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
EP0919233B8 (en) Therapeutic agent for kidney diseases
TW358809B (en) Phenylamidinothiophene compound and anti-inflammatory agent containing the same
TW273511B (en)
ES2101620A1 (en) New compound derived from chromene
DE69903346T2 (en) 22S-HYDROXYCHOLESTA-8,14-DIEN DERIVATIVES WITH MEIOSE REGULATING ACTIVITY

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase